The investment comprises £935k from Northstar Ventures, £150k from Creative UK, and funding from angel investors.
"We are excited to provide further support for MySalesCoach which has grown significantly since our initial investment in 2022 and is now well placed to scale further. Utilising our investor network to introduce Creative UK and new angel investors has provided additional capital to further accelerate the next stage of the business’ growth. MySalesCoach’s use of AI shows how businesses in the North East are adopting the latest technologies to deliver inventive solutions that make a real difference to their customers. We look forward to working with MySalesCoach in the next stage of their development and to seeing the business continue to flourish."
Symvan Capital backs Bristol artificial intelligence startup Tikos to address the black box problem.
"We’re excited to support Mike and Don in making AI systems trustworthy and compliant, addressing one of the most urgent challenges in AI. With over a decade of proprietary research, their ability to retrofit explainability and auditability into existing models is game-changing for regulated industries and high-stakes AI applications."
The Series C round was co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund to support international expansion and clinical studies.
"We would like to thank all the investors that participated, including Parkwalk and Boehringer Ingelheim Venture Fund for their continued support, and welcome Hostplus, all of whom recognise the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients. We will continue to harness our position and experience as a European market leader to achieve broad success in the US, helping improve patient care and access to life-changing therapies."
The agritech startup closed a round backed by biotope, Planetary Impact Ventures, and PINC to accelerate its digital tool development.
"Soil is the foundation of our food system, but modern agriculture has strained its health. The soil microbiome holds the key to restoring fertility, resilience, and reducing reliance on synthetic inputs. By unlocking its potential, we can help farmers produce food sustainably while regenerating the land for future generations."
The financing from Sofinnova Partners and Old College Capital will support the launch of precision fibrosis therapeutics.
"Launching Forth Tx through Sofinnova’s biotech accelerator has allowed us to translate years of our multiomics-driven research into precision therapies that we hope will transform patients’ lives. Fibrosis is an area of huge unmet medical need, and I’m delighted to be working with Alex and the Sofinnova team, as well as OCC, to deliver potent, new treatments for patients with fibrosis."
— Neil Henderson, Chair of Tissue Repair and Regeneration at the University of Edinburgh
